Subscribe To

Price Alert Latest News Economic Calendar News

SLRN / Why Acelyrin Stock Plummeted 59% This Week

Acelyrin's izokibep failed to meet statistical significance in its primary endpoint in a clinical trial evaluating the drug for the treatment of a skin inflammatory disorder. Shares of the biopharma company fell more than 50%, wiping out all of its post-IPO gains. Read More

Demo Live Account See Partner Details

Content Topics

Acelyrin

Stock

Plummeted

This

Week

SLRN

Posted: Sep 15 2023, 17:39

Author Name: The Motley Fool

SLRN News

By The Motley Fool
September 15, 2023

Why Acelyrin Stock Plummeted 59% This Week

Acelyrin's izokibep failed to meet statistical significance in its primary endpoint in a clinical trial evaluating the drug for the treatment of a ski

By Zacks Investment Research
September 13, 2023

ACELYRIN (SLRN) Fails to Meet Goal in HS Study, Stock Down 54%

ACELYRIN (SLRN) fails to achieve statistically significant primary endpoint result in the hidradenitis suppurativa study of its lead candidate, izokib

By Schaeffers Research
September 12, 2023

Pharma Stock Plummets on Skin Disease Trial

Publicly traded since May, Acelyrin Inc (NASDAQ:SLRN) stock is plummeting to record lows today.

By Proactive Investors
September 12, 2023

Acelyrin stock collapses after skin drug trail failure

Acelyrin Inc (NASDAQ:SLRN) collapsed, down some 58% ahead of Tuesday's open, after the company revealed the failure of its clinical trial which attemp

By InvestorPlace
September 12, 2023

Why Is Acelyrin (SLRN) Stock Down 58% Today?

Acelyrin (NASDAQ: SLRN ) stock is falling hard on Tuesday after the biopharma company announced clinical trial results. That bad news for investors i

By Reuters
September 12, 2023

Acelyrin tumbles after skin disease drug fails key trial

Shares of drug developer Acelyrin slumped 57% in premarket trading on Tuesday after the company's experimental lead drug failed to show it was effecti

By Proactive Investors
May 8, 2023

Acelyrin shares jump after one of the biggest IPOs in years

Acelyrin shares have added about 30% after the late-stage clinical biopharma raised $540 million during an upsized initial public offering (IPO). This

By Seeking Alpha
May 7, 2023

U.S. IPO Weekly Recap: Kenvue And ACELYRIN Fire Up The IPO Market, Raising A Combined $4.3 Billion

The month of May started off with two large IPOs, Kenvue and ACELYRIN. Two blank check IPOs also priced this past week.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.